SPG(SH:600529) Sou Hu Cai Jing·2025-06-23 11:31Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. is experiencing a decline in stock price and has a lower PE ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Shandong Pharmaceutical Glass closed at 22.17 yuan, down 1.55%, with a rolling PE ratio of 15.55 times and a total market capitalization of 14.712 billion yuan [1]. - The company operates in the pharmaceutical glass packaging sector, focusing on the research, production, and sales of glass bottles, rubber stoppers, and bottle caps [1]. - The company has been recognized with a new provincial engineering research center and has received the title of "National Manufacturing Single Champion Enterprise," highlighting its leading position in the field [1]. - The "Key Technology and Industrialization of Pharmaceutical Glass Bottle Manufacturing" project won two prestigious industry awards, showcasing its technological innovation and industrial value [1]. Financial Performance - In the first quarter of 2025, the company reported revenue of 1.242 billion yuan, a year-on-year decrease of 1.97%, while net profit was 224 million yuan, a year-on-year increase of 1.29%, with a sales gross margin of 30.21% [1]. Industry Summary - The average PE ratio for the medical device industry is 48.89 times, with a median of 35.79 times, positioning Shandong Pharmaceutical Glass at the 37th rank within the industry [1][2]. - The company has 70,488 shareholders as of March 31, 2025, an increase of 6,223 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1].